477888-48-5
Chemical Structure
Pyrrothiogatain
- CAS No.: 477888-48-5
- Formula:C11H11NO2S
- Molecular Weight:221.28
IUPAC Name: 3-(2,5-dimethyl-1H-pyrrol-1-yl)thiophene-2-carboxylic acid
InChIKey: ISEFROSMDUZELK-UHFFFAOYSA-N
SMILES: O=C(C1=C(N2C(C)=CC=C2C)C=CS1)O
Biological Activity: Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC50 of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pyrrothiogatain | 96.76% | Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC50 of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nomura S, et al. Pyrrothiogatain acts as an inhibitor of GATA family proteins and inhibits Th2 cell differentiation in vitro. Sci Rep. 2019 Nov 22;9(1):17335. [Content Brief]
- [2]. Almuraikhy S, et al. Targeted Inhibition of GATA-3 by Pyrrothiogatain: Implications for Adipocyte Biology and Inflammatory Response. Cells. 2025 Jan 10;14(2):100. [Content Brief]
- [3]. Israeli M, et al. Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. Nat Commun. 2022 Apr 25;13(1):2237. [Content Brief]
- [4]. Kalim KW, et al. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity. J Immunother Cancer. 2022 Nov;10(11):e004806. [Content Brief]
